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ABSTRACT  
Objectives : A growing body of evidence emerges that obesity, metabolic syndrome, type 2 
diabetes and cardiovascular disease are intimately related to silent chronic inflammation. 
Methods : A narrative review summarizing the most recent data of the literature describing 
the pathological implications of various inflammatory markers in the blood and several key-
tissues of obese patients with cardiometabolic disorders. 
Results : Besides high-sensitive C-reactive protein, various circulating or in situ 
inflammatory markers have been identified, presumably reflecting the presence of 
inflammation in various key-organs (visceral adipose tissue, skeletal muscle, pancreatic islets, 
liver, intestine, arterial wall). Inflammatory markers predict the risk of developing type 2 
diabetes and cardiovascular disease in obese patients. Available data support the concept that 
targeting inflammation, not only reduces systemic inflammatory markers, but also improves 
insulin sensitivity and ameliorates glucose control in insulin-resistant patients. Potentially, 
this approach could also reduce the risk of cardiovascular complications associated with 
abdominal obesity and type 2 diabetes.  
Conclusion : These observations confirm the role of inflammation in cardiometabolic 
diseases and  pave the route for the development of new pharmacological strategies that aim 
at reducing inflammation, especially in patients with type 2 diabetes. 
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1. Introduction 
The modern world is currently facing an epidemic of obesity and associated metabolic 
pathologies, including metabolic syndrome (MetS) and type 2 diabetes (T2DM). There is a 
strong relationship between abdominal obesity and T2DM.
1
 The pathophysiology of T2DM is 
rather complex with multiple actors playing a role to reduce tissue insulin sensitivity and 
diminish insulin secretion capacity by the β-cell.2,3 T2DM develops when islet β-cells are 
deficient in producing sufficient insulin to overcome peripheral insulin resistance (IR), and 
there is a growing body of evidence for the key-role of inflammation in both IR and β-cell 
failure.
4,5
 Cellular and humoral inflammation is located not only in adipose tissue (more 
particularly visceral adipose tissue or VAT), but also in skeletal muscle, liver and pancreatic 
islets, which may explain both tissue IR and β-cell progressive failure (Figure 1). MetS is 
closely related to IR,
6
 and both MetS and T2DM are important cardiovascular risk factors.
7
 
Almost two third of patients with T2DM will die from a cardiovascular disease (CVD).
7
 The 
initiation and progression of atherosclerotic lesions is currently understood to also have major 
inflammatory influences that encompass components of both the innate and acquired immune 
systems.
8
 Recent data support the hypothesis that inflammatory mediators of atherosclerosis 
may converge on the central role of tumour necrosis factor-alpha (TNF-α), interleukin-1 (IL-
1), and interleukin-6 (IL-6) signalling pathway.
9
 Thus, there are closed interactions between 
cytokines and inflammatory cells in islet dysfunction, IR and vascular disease.
10
 Thereby, 
nutritional and pharmacological strategies that inhibit the various inflammatory pathways 
responsible for obesity-associated metabolic complications and atherosclerosis are the subject 
of current intensive research (Figure 2).
9,
 
11,
 
12
  
 
2. Role of inflammation in cardiometabolic disorders 
 
2.1. Inflammation and visceral adipose tissue : role in metabolically unhealthy 
obese phenotype  
Abdominal obesity corresponds to a sub-clinical inflammatory condition that promotes 
the production of pro-inflammatory factors involved in the pathogenesis of IR.
13, 14
 
Inflammatory cytokines, including TNF-α, have been shown to promote IR, and altered 
expression of cytokines (adipokines) in obese adipose tissue is thought to be an important link 
between obesity and IR.
15
 For instance, the metabolically unhealthy obese phenotype seems to 
be associated with an increased activation of the NLPR3 (Nucleotide-binding oligomerization 
  
domain, Leucine-rich Repeat and Pyrin domain containing 3) inflammasome in macrophages 
infiltrating VAT, and a less favourable inflammatory profile compared with the metabolically 
healthy obese  phenotype.
13
 Indeed, we found an increased secretion of IL-1β, increased 
expression of IL1B and NLRP3, increased number of adipose tissue macrophages and 
decreased number of regulatory T cells in the VAT of metabolically unhealthy obese patients 
compared with metabolically healthy obese patients and lean subjects. In macrophages 
derived from VAT, both caspase-1 activity and IL-1β levels were higher in metabolically 
unhealthy obese patients than in metabolically healthy patients.
13
 
 
2.2. Inflammation and skeletal muscle : role in insulin resistance 
Skeletal muscle plays a key role in insulin sensitivity. IR in presence of obesity was 
mainly explained for decades by the Randle’s substrate competition theory, the muscle 
utilizing free fatty acids instead of glucose as energy source.
1
 Later on, the presence of ectopic 
fat within the muscle has been described and intramuscular triglyceride depots were 
considered as major players in the muscular metabolic disorders.
16
 Now, muscle 
inflammation is emerging as a potential contributor to IR. Recent reports show that 
inflammatory macrophage numbers within muscle are elevated during obesity and 
that muscle cells in vitro can mount autonomous inflammatory responses under metabolic 
challenge.
17
 Finally, the role of various myokines (like irisin) released by skeletal muscle has 
been pointed out  in the regulation of inflammation and IR.
18
 
 
2.3. Inflammation and pancreatic islets : role in β-cell failure 
It is becoming clear that inflammation plays a key role in the development of β-cell 
dysfunction. Inflammatory changes, including accumulation of macrophages, have been 
documented in islets of T2DM patients.
19
 However, little is known about the nature of the 
pro-inflammatory response within the islet, and there is considerable debate about the triggers 
for islet inflammation, which may be systemically derived and/or tissue-specific.
20 There are 
strong arguments to consider that the IL-1β pathway plays a key-role in the pathology of the 
immune system that leads to islet inflammation and subsequent β-cell failure.21 Toll-like 
receptors 2 and 4 and the NLRP3 inflammasome have been recently proposed as triggers for 
islet inflammation that mediates β-cell dysfunction in T2DM.20 Therapeutically targeting IL-
1β pathway or these receptors may improve hyperglycaemia and protect the β-cell in T2DM.21 
 
  
2.4. Inflammation and liver : role in non-alcoholic fatty liver disease 
Abdominal obesity and T2DM are strongly associated with non-alcoholic fatty liver 
disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
22
 NAFLD is considered as an 
ectopic fat syndrome, which is closely related to IR.
16
 The pathophysiology of NASH 
involves two steps : 1) IR, which causes steatosis; 2) and oxidative stress, which produces 
lipid peroxidation and activates inflammatory cytokines.
22
 Accumulating evidence reveals 
that NAFLD and hepatic IR are strongly related to inflammation. 
23
 Cytokines and adipokines 
play a pivotal role in inflammatory processes. In addition, these inflammatory mediators 
regulate various functions including metabolic energy balance, inflammation, and immune 
response. 
23
 During development of NASH, CCL2 [chemokine (C-C motif) ligand 2] and its 
receptor are up-regulated in the liver, where they promote macrophage 
accumulation, inflammation, fibrosis, and steatosis. CCL2 signaling thereby links hepatic and 
systemic inflammation related to metabolic disorders and IR.
24
 Finally, recent data suggest 
that altered intestinal microbiota (dysbiosis) may stimulate hepatic fat deposition through 
several mechanisms including regulation of gut permeability and increased low-grade 
inflammation.
25
 The identification of subjects who may progress from fatty liver to NASH, 
and from NASH to fibrosis/cirrhosis is an important clinical challenge as well as the finding 
of appropriate strategies that could prevent such deleterious process. 
 
2.5. Inflammation and intestine : role of microbiota 
Gut microbiota has emerged as one of the key factors regulating early events 
triggering inflammation associated with obesity and metabolic dysfunction.
26
 This effect 
seems to be related to diet- and obesity-associated changes in gut microbiota composition and 
to increased translocation of immunogenic bacterial products, which activate innate and 
adaptive immunity in the gut and beyond, contributing to an increase in inflammatory tone.
27
 
Innate immune receptors, like Toll-like receptors (TLRs), are known to be up-regulated in the 
tissue affected by most inflammatory disorders and activated by both specific microbial 
components and dietary lipids. This triggers several signaling transduction pathways, leading 
to inflammatory cytokine and chemokine (TNF-α, IL-1) production and to inflammatory cell 
recruitment, causing IR and NAFLD. 
25,26
 Because perturbation of the intestinal microbiota 
and subsequent changes in intestinal permeability are potential triggers of inflammation in 
obesity, prebiotic and probiotic approaches are presented as interesting tools to counteract the 
drop in target bacteria and thereby improve host metabolism.
27
 Thus, further characterisation 
  
of the mechanisms underpinning the triggers of such inflammatory responses in obese 
individuals could offer unique opportunities for intervention strategies to help ameliorate the 
risk of obesity-associated disease such as T2DM.
28
 
 
2.6. Inflammation and arterial wall : role in atherosclerosis 
Atherosclerosis, the major cause of CVD, is a chronic inflammatory condition 
involving immune competent cells in lesions producing mainly pro-inflammatory 
cytokines.
8,29
  Even though inflammation and immune activation may be more pronounced 
in atherosclerosis in T2DM, no major differences could be detected between diabetic and non-
diabetic individuals.
29
 The cause of immune activation is not known and different mutually 
non-exclusive possibilities exist. Oxidized forms of low density lipoproteins (oxLDL), which 
are abundant in atherosclerotic plaques, have proinflammatory and immune-stimulatory 
properties, cause cell death at higher concentrations and contain inflammatory phospholipids 
with phosphorylcholine as an interesting epitope. Chronic inflammation may lead to plaque 
rupture, the major direct cause of CVD death.
8
 To prove that inflammation plays a causal role 
in atherosclerosis and CVD, clinical studies with anti-inflammatory and/or immune-
modulatory treatment are needed and some of them are under way.
9
 
 
2.7. Inflammation and small vessels : role in diabetic complications 
The underlying mechanisms of diabetic complications imply many biochemical pathways, 
including also inflammation.
30,31
 Many lines of evidence, ranging from in vitro experiments 
and pathological examinations to epidemiological studies, show that inflammation is a 
cardinal pathogenetic mechanism in diabetic nephropathy.
32,33
 In vitro studies have cast light 
on the cellular mechanisms whereby diabetes triggers inflammation and in 
turn inflammation magnifies the kidney injury. Translation of this basic science knowledge 
into potential practical clinical applications is matter of great interest for future research.
34, 35
 
Local inflammation plays also a key role in the development of diabetic retinopathy.
36
 
Inflammation in the diabetic retina is mediated by leukocyte adhesion to the retinal 
vasculature and chemokine-mediated alteration of the blood-retinal barrier.
37
 Thus, 
modulation of inflammatory processes to attenuate these diabetic complications is a matter of 
major interest for researchers today. 
 
  
3. Markers of inflammation and risk of T2DM, CVD and diabetic 
complications 
Various markers of inflammation have been shown to be associated with a higher risk 
to develop T2DM and CVD.
14
 Among those markers, C-reactive protein (CRP), especially 
high-sensitive (hs) CRP, was the most extensively studied.  
 
3.1.Inflammatory markers and risk of incident T2DM 
In a recent meta-analysis, elevated CRP levels were significantly associated with 
increased risk of T2DM (relative risk [RR] 1.26 [95% confidence interval or 95% CI 1.16-
1.37]) based on results of 22 studies, and a significant dose-response association was also 
observed between the levels of its inducer IL-6 and later occurrence of T2DM (RR 1.31 [95% 
CI 1.17-1.46]).
38
 Alternatively, low levels of anti-inflammatory proteins such as adiponectin, 
omentin and IL-10 may also be associated with later onset of T2DM, although sometimes 
conflicting results regarding their association with T2DM have been reported.
39
 
 
3.2.Inflammatory markers and risk of CVD 
The Emerging Risk Factors Collaboration group, in a meta-analysis of 52 prospective 
studies on people without a CVD history, reported that measurements of two inflammatory 
markers such as CRP and fibrinogen help in the prediction of cardiovascular events.
40
 In 
meta-analysis of up to 29 population-based prospective studies, adjusted relative risks for 
non-fatal myocardial infarction or coronary heart disease death per 1-standard deviation 
higher levels were: 1.25 (95% CI 1.19-1.32) for IL-6; 1.13 (1.05-1.20) for IL-18; 1.07 (0.97-
1.19) for matrix metalloproteinase-9 (MMP-9); 1.07 (0.95-1.21) for soluble CD40 ligand 
(sCD40L); and 1.17 (1.09-1.25) for TNF-α. Several different pro-inflammatory cytokines are 
each associated with coronary heart disease risk independent of conventional risk factors and 
in an approximately log-linear manner. The findings lend support to the inflammation 
hypothesis in vascular disease, but further studies are needed to assess causality. 
41
 Whether 
inhibiting inflammation with specific agents, beyond statin therapy, would result in reducing 
the incidence of CVD in high-risk patients, including those with MetS or T2DM, deserves 
further specific trials.
42, 43
 
 
3.3.Inflammatory markers and risk of diabetic complications 
  
Inflammation appears to play a key-role in the development of diabetic complications. 
Increased CRP, IL-6, and TNF-α, and especially interstitial cellular adhesion molecule-1, 
vascular cellular adhesion molecule-1 (VACM-1), and E-selectin are associated with 
nephropathy, retinopathy, besides CVD, in both type 1 diabetes and T2DM.
44
 In diabetic 
patients, higher CRP levels, but not markers of endothelial function, may be related to more 
severe diabetic retinopathy. This finding suggests that inflammatory processes are involved in 
the development and progression of severe diabetic retinopathy.
45
 
 
4. Diet and inflammatory markers 
Dietary patterns high in refined starches, sugar, and saturated and trans-fatty acids, 
poor in natural antioxidants and fiber from fruits, vegetables, and whole grains, and poor in 
omega-3 fatty acids may cause an activation of the innate immune system, most likely leading 
to most an excessive production of proinflammatory cytokines associated with a reduced 
production of anti-inflammatory cytokines.
46
 The Mediterranean diet may not only act on 
classical risk factors (lipid parameters) but also on inflammatory biomarkers such as adhesion 
molecules and cytokines.
47
 In a systematic review of saturated fatty acids (SFAs) on 
inflammation and circulating levels of adipokines, significant positive associations were 
observed between saturated fatty acids and hs-CRP, soluble intercellular adhesion molecule-1 
(ICAM-1) and IL-6, whereas no significant associations were observed with E-selectin, TNF-
α, granulocyte-macrophage colony-stimulating factor, fibrinogen, and adiponectin.48 SFAs, 
unlike unsaturated fatty acids, have recently been proposed as triggers of the NLRP3 
inflammasome.
49
 We recently reviewed how SFA-mediated NLRP3 inflammasome activation 
could contribute to the development of both insulin resistance and deficiency associated with 
obesity/T2DM.
50
  
Previous research has shown that nutrients and certain food items influence 
inflammation but little is known about the associations between diet, as a whole, 
and inflammatory markers. In a Belgian cross-sectional study (ASKLEPIOS), multivariable 
analyses showed significant positive associations between the food frequency questionnaire 
(FFQ)-derived dietary inflammatory index and the inflammatory markers IL-6 and 
homocysteine, but no significant associations with the inflammatory markers CRP and 
fibrinogen.
51 
  
5. Targeting inflammation , a new paradigm in cardiometabolic 
diseases 
5.1. Anti-inflammatory effects of Mediterranean diet 
The whole diet approach seems particularly promising to reduce the inflammation 
associated with the metabolic syndrome
46
. A recent systematic review and meta-analysis of 
interventional trials provides evidence that a Mediterranean diet decreases 
various inflammatory markers : hs-CRP, IL-6, and ICAM-1.
52 
Because unsaturated fatty acids, especially ω-3 fatty acids, inhibit NLRP3 
inflammasome activation in various settings, the potential clinical use of ω-3 fatty acids as 
anti-inflammatory compounds may be considered.
49,50
 
 
 
5.2. Anti-inflammatory effects of lipid-lowering agents 
Lipid-lowering agents (statins, ezetimibe and fibrates) may reduce markers of 
inflammation, especially CRP.
53, 54
Most of the anti-inflammatory effect of LDL-lowering 
therapies is related to the magnitude of change in LDL while the potential non-LDL effects of 
statins on inflammation appear much smaller in magnitude.
55
 However, in the JUPITER trial 
of apparently healthy persons without hyperlipidaemia but with elevated hsCRP levels, 
rosuvastatin significantly reduced hs-CRP levels and the incidence of major cardiovascular 
events.
56
 In a prospective study of this  trial, achieved hsCRP concentrations with rosuvastatin 
were predictive of event rates irrespective of the lipid endpoint used.
57
 However, a recent 
meta-analysis of 22 randomized trials showed that statin-induced changes in CRP do not 
correlate with major cardiovascular events apart from the risk of myocardial infarction nor 
with overall survival in high-risk patients.
58
 
 
5.3. Anti-inflammatory effects of blocking the renin-angiotensin-aldoserone 
system 
Evidence shows that inhibition of renin-angiotensin-aldosterone system (RAAS) 
positively influences vascular remodeling thus improving CVD outcomes. The beneficial 
vascular effects of RAAS inhibition are likely due to decreasing vascular inflammation, 
oxidative stress, endothelial dysfunction, and positive effects on regeneration of endothelial 
progenitor cells. Inflammatory factors such as ICAM-1, VCAM-1, TNF-α, IL-6, and CRP 
  
have key roles in mediating vascular inflammation and blocking RAAS negatively modulates 
the levels of these inflammatory molecules.
59
 
5.4. Anti-inflammatory effects of antidiabetic agents 
The management of T2DM is evolving
60
 and many therapies are now available.
61
 
Among currently used glucose-lowering agents, several of them also exert some anti-
inflammatory effects, which may contribute to impact positively patient’s outcome.62 Overall, 
insulin-sparing agents or insulin-sensitizers such as metformin and thiazolidinediones 
(glitazones) appear to exert a greater anti-inflammatory activity than insulin-secreting agents 
as sulphonylureas or glinides.
62
 Incretin-based therapies (dipeptidyl peptidase-4 inhibitors and 
glucagon-like peptide-1 receptor agonists) showed  promising results with reduction in 
various inflammatory markers in patients with T2DM, but these preliminary results should be 
confirmed and if possible translated into improvement of hard clinical outcomes.
62
 An 
emerging body of evidence also suggests that insulin suppresses the inflammatory process, 
not only through preventing hyperglycaemia but also by modulating key inflammatory 
molecules.
63  
5.5.Innovative anti-inflammatory strategies 
The prominent role of inflammation paves the route for future specific anti-
inflammatory therapies to prevent or treat T2DM and CVD. 
64-67
 Numerous novel strategies, 
using either small molecules or monoclonal antibodies, have been recently investigated and 
are still in development : approaches targeting IKK-b-NF-kB (salicylates, salsalate), TNF-α 
(etanercept, infliximab, adalimumab), IL-1β (anakinra, canakinumab) and IL-6 (tocilizumab), 
AMP-activated protein kinase activators, sirtuin-1 activators, mTOR inhibitors and CCR-2 
inhibitors
12
. Because the increasingly recognized role of infammasome in obesity-associated 
metabolic disorders such as T2DM,
13,68
 IL-1 blocking strategies are specific pathway 
targeting therapies in autoinflammatory disorders
69
 and may open new perspectives for the 
management of chronic diseases like T2DM.
70
 However, even promising, the observed 
metabolic effects remain rather modest in most clinical trials published so far. The potential 
use of combined anti-inflammatory agents targeting both insulin resistance and insulin 
secretion appears appealing but remains unexplored. As recently reviewed,
9 emerging anti-
inflammatory approaches to vascular protection can be categorized into two broad groups, 
those that target the central IL-6 inflammatory signalling pathway and those that do not. Large 
scale prospective clinical trials are underway to investigate the safety and efficacy of different 
  
anti-inflammatory drugs.
12
 Further evidence is needed to support the concept that targeting 
inflammation pathways may represent a valuable option to tackle the cardiometabolic 
complications of obesity. 
 
Conclusion 
There is a growing body of evidence that metabolic diseases that accompanied abdominal 
obesity, like MetS and T2DM, and lead to CVD, are associated with activation of the innate 
immune system in various tissues involved in metabolism. All these pathologies are 
characterized by elevated proinflammatory factors (TNF-α, IL-1, IL-6), decreased anti-
inflammatory factors (adiponectin) and the presence of activated immune cells (macrophages, 
T lymphocytes). Inflammation is present both in tissues implicated in insulin sensitivity 
(adipose tissue, skeletal muscle, liver), contributing to worsen IR, and pancreatic islets, where 
it can induce β-cell dysfunction and death via intra-islet IL-1β activity. Thereby, inflammation 
may play a crucial role in the pathophysiology of T2DM. Furthermore, atherosclerosis, which 
is accelerated and more pronounced  in patients with MetS and T2DM and responsible for a 
high morbi-mortality rate in this population, is also characterized by increased silent 
inflammation, especially in the arterial wall. Patients with elevated hs-CRP levels are at 
higher risk to develop T2DM and CVD. Therefore, tartgeting inflammation with anti-
inflammatory agents make sense for the management of patients with T2DM and patients at 
high risk of CVD. Anti-inflammatory agents have shown favourable effects on surrogate 
endpoints (especially a significant reduction in various inflammatory markers among which 
hs-CRP), but the demonstration of a positive effect on hard metabolic and cardiovascular 
outcomes is still lacking. The results of several  ongoing prospective trials are awaited with 
great interest. 
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Figure 1 : Role of local and systemic inflammation in metabolic and vascular abnormalities. 
hs-CRP : high-sensitive C-reactive protein. NASH : non-alcoholic liver disease. VAT : 
visceral adipose tissue. 
 
  
  
Figure 2 : Various strategies targeting obesity-associated silent inflammation in 
cardiometabolic diseases. ACE : angiotensin-converting enzyme. ARA : Angiotensin receptor 
antagonists. RAAS : renin-angiotensin-aldosterone system. T2DM : type 2 diabetes mellitus. 
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